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ABSTRACT
More than ten years after the first biosimilars were authorized for use in the European Union,
Belgium still experiences limited competition from biosimilars, as exemplified by low market
shares. Achieving high biosimilar market shares is not necessarily a goal in itself, as cost savings
are also realized by mandatory price reductions on originator medicines in Belgium. However,
we believe that biosimilars play a role in ensuring the long-term sustainability of the off-patent
biologicals market. It is therefore crucial to list what has been done and what is needed to
support the Belgian government in establishing a policy framework for a competitive off-
patent biologicals market. We provide a comprehensive overview of the Belgian biosimilar
market, including existing hurdles for biosimilar use in Belgium. Based on these hurdles and
supplemented with learnings from other European countries, we propose practical recommen-
dations that can be implemented to overcome them. Several Belgian stakeholders had the
opportunity to comment on these recommendations. Specifically, we suggest to evolve
towards a long-term consistent, integrated policy framework via i) the creation of a proactive
and transparent climate supporting a level playing field for both biosimilar and reference
product, including public dissemination of how savings at the level of the Belgian healthcare
system are used, ii) investment in educational activities, including raising awareness of societal
responsibility, iii) enforcement of the practical implementation of public procurement law, and
iv) the development of incentives for physicians, who are key stakeholders in the Belgian off-
patent biologicals market.
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1 Current biosimilar landscape in Belgium
In January [1] 2020, 29 of the 54 biosimilars that
received marketing authorization for the European
Union were available and reimbursed in Belgium
[2,3]. These 54 biosimilars include two biosimilars for
bevacizumab that cannot yet be launched due to
ongoing exclusivity rights protection on Avastin® [4].
Table 1 presents in which treatment setting these
biosimilars are classified for use in non-hospitalised
patients, i.e. ambulatory patients in the hospital and
the retail setting. For ambulatory hospital patients,
biosimilars were available and reimbursed for all active
substances for which biosimilars could be marketed. In
the retail setting, biosimilars were not available nor
reimbursed for three of the nine reference products.
The launch of a medicine in a country often depends
on company strategies/choices. In July 2019, Sandoz
retracted its filgrastim biosimilar (Zarzio®) from the
Belgian market.
In the context of financing and reimbursement, bio-
logical medicines, including biosimilars, are treated in
the same way as other medicines and are financed by
the Belgian reimbursement agency (National Institute
for Health and Disability Insurance – NIHDI) via taxes,
compulsory health insurance via a sickness fund of
choice, and patient co-payments. For inpatients, the
use of medicines is included in a lump-sum co-
payment. For outpatients, including ambulant patients
in the hospital (e.g, for infliximab), co-payment
depends on different reimbursement categories. List
prices and reimbursed prices are coordinated on
a national level. Medicines used in the hospital setting
(inpatients and ambulant patients) are procured by
individual hospitals or hospital groups, which can
keep the savings they negotiate or obtain via tendering
(usually one-winner contracts). In this way, medicines
with higher reimbursement prices are favoured, as
higher absolute savings can be gained.Most biosimilars
and reference products that are used in the hospital
setting only, have therefore now the same list price.
Market shares for most biosimilars in Belgium were
in 2019 still below 20% (Figure 1). Higher market shares
were reached for filgrastim and infliximab biosimilars,
42% and 46%, respectively. Even with filgrastim being
available in the retail setting, most of the volume was
dispensed in the hospital setting (inpatients).
Over the last years, several policy measures related
to biosimilars have been implemented to enhance
competition in the Belgian off-patent biologicals mar-
ket (Table 2). Although the first biosimilar was
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authorised in 2006, it is noteworthy that, apart from
information on biosimilars on the website of the com-
petent authority, a decade elapsed before the Belgian
Ministry of Health and national authorities started to
take action regarding biosimilars in 2016. Four years
later, the market has evolved, however, the impact of
these policy measures is still limited.
In addition to measures specifically aiming to
enhance competition, a multitude of cost containment
measures have also been introduced that affect off-
patent biological products. These include the price
reduction measure for ‘old medicines’ (−17% on the
ex-factory price after 12 years of reimbursement; a revi-
sion to −19.75% is planned, but not yet implemented),
the ‘volume cliff’ (up to −12.05% depending on the
annual sales after 15 years of reimbursement, before
1 April 2019 this was fixed at −2.41%), and the price
reduction measure for biological medicines (−15%
after 18 years of reimbursement or in the first quarter
following biosimilar availability and reimbursement for
2 months; following revision: −20%) [5,6]. If the mea-
sure for ‘old medicines’ and ‘volume cliff’ are not yet
implemented when the entry of the biosimilar triggers
the measure for biological medicines, all price reduc-
tions are enforced at once (up to 38% price reduction)
[6]. This is called the ‘bio cliff’ and was introduced on
1 April 2018. A revision of these cost containment
measures was planned to be implemented on
1 April 2020, but has been postponed until further
notice due to the outbreak of the coronavirus and
has thus not been agreed on at the time of writing
[7]. This revision would also include that the
introduction of the biosimilar will no longer be needed
to trigger the ‘bio cliff’, and all these price reductions
will be applied when the biological product is reim-
bursed for 12 years (‘old medicines cliff’). Another cost
containment measure was introduced on
1 January 2017, and specified that, for biological med-
icines which have a biosimilar alternative, the reimbur-
sement to the hospitals has been lowered with 10%,
limiting reimbursement to only 90% of the amount
invoiced by the hospital [8]. With this measure the
government wanted to stimulate hospitals to apply
the law on public procurement. It is believed that this
was an important incentive for hospitals. From
1 April 2019, reimbursement was further lowered
from 90% to 85% [9], and following revision, this reim-
bursement is likely to be reduced to 70%. Since 2012,
biosimilars and their reference products can also be
included in reimbursement category F, where a fixed
reference price is set for reimbursement to the hospital
and any additional price differences need to be cov-
ered by the hospital. This was the case for short and
long acting epoetins in an attempt to level out price
differences and corresponding advantages of the
higher priced reference product in hospital procure-
ment procedures. Some products (short and long act-
ing epoetins and somatropin) are included in the
prospective hospital budget for medicines since 2012,
while these were previously invoiced based on actual
consumption [10]. Biosimilars are also part of quotas
for prescribing low-cost medicines [11]. However, as
there are mandatory price decreases for the reference
product as well as the biosimilar after entry of
Table 1. Reimbursed biosimilars in Belgium, classified by treatment setting for use in non-hospitalised patients (as of
January 2020) [3]. Marketing authorization dates for the European Union are indicated between brackets [2]. Molecules are
sorted from oldest (on top) to newest biosimilar marketing authorization for the European Union. Please note that marketing
authorization is not equal to access to treatment, since reimbursement and product launch usually occur later.
Hospital setting (ambulant patients) Retail setting
INN Brand name INN Brand name
Epoetin Binocrit® (27/08/2007) Somatropin Omnitrope® (11/04/2006)
Retacrit® (17/12/2007)
Infliximab Inflectra® (08/09/2013) Filgrastim Tevagrastim® (14/09/2008)
Remsima® (09/09/2013) Nivestim® (06/06/2010)
Flixabi® (25/05/2016) Accofil® (16/09/2014)
Zessly® (17/05/2018)
Follitropin alfa Bemfola® (25/03/2014) Follitropin alfa Ovaleap® (26/09/2013)
Rituximab Truxima® (16/02/2017) Insulin glargine Abasaglar® (08/09/2014)
Rixathon® (14/06/2017)
Trastuzumab Ontruzant® (14/11/2017) Etanercept Benepali® (12/01/2016)
Herzuma® (07/02/2018)
Kanjinti® (15/05/2018)
Trazimera® (25/07/2018)
Ogivri® (11/12/2018)
Pegfilgrastim Pelgraz® (20/09/2018) Enoxaparin sodium -
Pelmeg® (19/11/2018)
Ziextenzo® (21/11/2018)
Teriparatide -
Insulin lispro -
Adalimumab Amgevita® (20/03/2017)
Imraldi® (23/08/2017)
Hyrimoz® (25/07/2018)
Hulio® (15/09/2018)
Idacio® (1/04/2019)
INN: International non-proprietary name
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biosimilars, both reference and biosimilar products are
defined as being low-cost medicines, hence limiting
the impact of this measure on the uptake of
biosimilars.
Even with several national measures and initiatives
to increase competition (see Table 2), biosimilar uptake
in Belgium remains limited (Figure 1) and this might
indicate that the entry of biosimilars is not fully lever-
aged. We build on a report from the Belgian Health
Care Knowledge Centre (KCE) on biosimilars and the
work of Dylst et al. [10,12] from 2013 and 2014, respec-
tively, and look again anno 2019 whether earlier iden-
tified barriers are still valid. In addition, we discuss
potential reasons as to why biosimilar uptake in
Belgium is still limited, and adopt learnings from bio-
similar policies and practices in Europe to serve as
input to guide policy decisions in Belgium and poten-
tially increase competition in the Belgian off-patent
biologicals market.
This perspective paper is informed by face-to-face
discussions with various Belgian stakeholders to seek
confirmation for the applicability of the factors identi-
fied by the research team as influencing market
dynamics of originator biological and biosimilar pro-
ducts. The discussions offered as well the opportunity
to Belgian stakeholders to add new suggestions for
improving the current biosimilar policy framework.
The interviewed stakeholders were also given the
opportunity to comment on the draft paper. Via this
process we wanted to ensure that practical recommen-
dations are provided that allow for a certain consensus
among stakeholders. Even though the number of inter-
viewees (17) and selected sample (originator and bio-
similar industry, hospital pharmacists, physicians, and
authorities) might not guarantee general consensus,
the authors put forward their own key takeaways to
increase competition in the Belgian off-patent biologi-
cals market.
2. Barriers to biosimilar uptake in Belgium
In 2013, the KCE report on barriers and opportunities for
biosimilars in Belgium described the following main
barriers to the market uptake of biosimilars in Belgium:
a lack of knowledge on biosimilars that may be linked to
the use of non-effective information dissemination
channels in an attempt to inform stakeholders, a lack
of confidence in the biosimilar pathway and services
from biosimilar companies, loyalty to the innovator
company and its value-added services, and large dis-
counts offered on the reference product in the hospital
setting [10]. Similar barriers have been identified by
Dylst et al. in 2014, i.e. a lack of confidence, concerns
on interchangeability and substitution, and a hospital
financing system that incentivizes the use of the origi-
nator product [12]. Possible solutions to overcome these
barriers are suggested, such as providing objective
information to stakeholders, a reform of the hospital
finance system, and the introduction of prescription
quota for biosimilars.
Some of these earlier identified barriers seem to be
partly overcome. The barrier of knowledge and trust in
biosimilars is perceived not to be a key barrier any-
more; even though there might still be a need for clear
and neutral communication on biosimilars and further
education. The position statement of the Belgian com-
petent authority (2009, see Table 2) is a step in the
good direction, but is insufficient to influence physi-
cians’ prescribing behaviour. In addition, although
invited to the symposium organized by the competent
authority in 2018, the presence of physicians as an
important stakeholder was minimal compared to
Figure 1. Biosimilar market shares in Belgium, based on volume (defined daily doses) versus the reference product, for the years
2015 to 2019. Data for 2019 are partly extrapolated (EP) based on 6 months of hospital data and 9 months of data for the retail
setting. Data were provided by the Belgian reimbursement agency RIZIV/INAMI/NIHDI (Farmanet and DOC PH databases).
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other stakeholders. A second barrier to biosimilar
uptake, describing a hospital financing system that
favours the higher-priced originator product, has
been overcome, as almost all biosimilars and reference
products that are used in the hospital setting have the
same list price or reimbursement price, thereby provid-
ing a level playing field for tendering. However,
although the barriers identified as key in 2013 and
2014 are now largely resolved and uptake remains
still limited, this implies that other barriers and poten-
tially new barriers play a role.
The climate in Belgium is historically innovator
minded as a result of a large pharmaceutical R&D
footprint (first place in R&D investments per inhabitant
and third place in R&D employment per inhabitant,
within the European Union [28]). This is reflected in
a strong lobby organisation from the innovator indus-
try, politicians are careful not to take measures affect-
ing employment in the pharmaceutical sector, and
brand loyalty of physicians. A perception exists that
rumours from the originator industry on immunogeni-
city and switching slowed down acceptance of biosi-
milars. This landscape might evolve with big pharma
companies originally investing in innovator molecules
entering the biosimilar market. In addition, as R&D
efforts and production of medicines are for the global
market these days, employment in the pharmaceutical
sector will not only depend on market shares in
Belgium. Furthermore, marketing efforts are tradition-
ally lowered after patent expiry. So the will to safe-
guard the R&D footprint should not be a factor
impeding competition in the off-patent biologicals
market.
One structural barrier to biosimilar uptake seems to
be that there are no tangible benefits and incentives
for authorities, physicians, pharmacists, patients and
hospitals to use biosimilars. The reimbursement
agency realizes cost savings via mandatory price
Table 2. Implemented policy measures related to biosimilars to enhance competition in the Belgian off-patent biologicals market.
Year Type of measure Details
2009 Position statement In 2009, the Belgian competent authority first published information on biosimilars on their website and takes a position
on switching and substitution of biological products. This information is regularly updated [13,14].
2016 Prescription target The Pact of the future that was signed in July 2015 has led in January 2016 to the establishment of a covenant between the
government, the pharmaceutical industry and the medical sector, in which they stimulate physicians to prescribe at
least 20% biosimilars for treatment-naive patients [15]. They also state that switching from the originator to the
biosimilar product is acceptable.
2016 Working group With the establishment of the covenant, a working group on biosimilars was composed that included representatives from
the Belgian reimbursement agency, the competent authority, industry associations, and academia.
2016 Monitoring In the context of the covenant, biosimilar uptake is monitored and assessed every three months, at least up to June 2017,
and compliance of hospitals with the law on public procurement was raised as a point of interest [8]. In December 2018,
the Belgian reimbursement agency shared few data on the use of biosimilars since the establishment of the covenant on
their website [16]. Reports on biosimilar uptake are shared yearly with members of the working group on biosimilars,
but are not made publically available.
2016 Circular letter on
tendering
In January 2016, a circular letter from the Minister of Social Affairs and Health addressed hospital administrators, the
pharmaceutical and therapeutic committees of hospitals, and hospital pharmacists to conform to the law on public
procurement of 15 June 2006, enacted since 1 July 2013, and to include biosimilars in the same lot as their reference
product [17]. In addition, the Minister emphasizes that the award criteria must be related to the subject of the contract,
and also urges to include a clause that allows hospitals to terminate a contract earlier and open a new tender in case
new alternatives are available.
2018 Education In February 2018, the Belgian competent authority organised a symposium on biological medicines in Belgium, which
focused on the use of biosimilars in Belgium, experiences from patient organisations, physicians and other healthcare
professionals, and learnings from Norway and the Netherlands [18].
2018 Education In December 2018, a joint media campaign between the competent authority and the reimbursement agency was set up
to provide information on biological medicines, including biosimilars, to patients and healthcare professionals [19,20].
In the context of this campaign, a website was launched with definitions of a biological medicine and of a biosimilar
[21]. Also radio spots, posters, patient brochures and banners on websites and social media were used to communicate
to the general public.
2018 Reimbursement From 1 July 2018, the reimbursement procedure for biosimilars has been simplified and shortened from 180 days to
90 days [22].
2019 Financial incentive For the year 2019, the use of a financial incentive was piloted to increase prescription of biosimilar adalimumab and
etanercept in the retail setting [23]. When an annual target of 5%, 10% or 20% of prescribed adalimumab and
etanercept biosimilars is reached, €750, €1000 or €1500 will be paid, respectively, to the individual physician to
compensate for their efforts to communicate with patients.
2019 Champion In 2019, a ‘programme manager biological and biosimilar medicines’ was assigned by the Belgian reimbursement agency
to study the Belgian biosimilars landscape and come up with solutions to create a dynamic biologicals market [16,24].
2019 Research For 2019, the reimbursement agency planned to set up a study to map the rationale of physicians behind prescribing
a biosimilar or originator product, concerns of physicians and patients, and how much time is spent to communicate
with patients on biosimilars [16]. This study is commissioned to a university research group and planned for 2020.
2019 Circular letter on
tendering
In June 2019, the competent authority addressed via a circular letter the hospitals, pharmaceutical companies and
wholesalers to correctly apply the law on public procurement from 17 June 2016 and the law on medicines from
25 March 1964 [25]. This was done in response of a communication in March of the same year by the Public
Procurement Service of the Federal Public Service Chancellery of the Prime Minister, who studied at the request of the
Minister of Social Affairs and Health whether the use of additional benefits as an award criterion is conform with
relevant legislation [26].
2019 Working group In November 2019, the Federal Council of Ministers, in the context of determining the healthcare budget for 2020, decided
that new measures are needed to increase biosimilar uptake [27]. A new working group is established to give advice by
the beginning of March 2020 on how to improve competition in the biologicals market.
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decreases on the originator product (although, with-
out the entry of biosimilars, the reduced reimburse-
ment to the hospitals will not be triggered). Physicians
do not feel involved because the cost savings flow
back to the reimbursement agency or hospital man-
agement and often not to the department or indivi-
dual physician. Moreover, switching patients takes
time for which physicians are not remunerated.
Pharmacist remuneration and patient co-payments
do not differ between biosimilar and reference pro-
duct. Hospitals, on the other hand, have a financial
incentive to tender in order to increase savings.
However, originator companies are able to provide
considerable discounts and can prolong the exclusivity
contract just before patent expiry, avoiding the admin-
istrative burden of opening a tender.
In addition to these general barriers, setting-specific
barriers can be identified.
2.1. Hospital market
A first hurdle for the use of biosimilars in the hospital
setting is related to the opening of tenders. Several
reasons might explain why hospitals do not open new
contracts when a biosimilar enters the market: a) ten-
ders require considerable time efforts from hospital
pharmacists, b) hospitals might initially wait until
more players can offer a bid, c) the innovator’s reach
and possible benefits to hospitals can play a role in the
lack of willingness to open a tender when the biosimi-
lar enters, d) legally correct new exclusivity contracts
with potentially substantial discounts are concluded
just before biosimilars enter the market, and f) dis-
counts are given on subcutaneous alternatives, limit-
ing the need for a new contract on the intravenously
administered biosimilar product.
To illustrate this, trastuzumab biosimilar Herzuma®
launched in August 2018 (others in 2019), whereas the
first notice of intent to tender was only published in
March 2019 [29]. Since then, five tenders have been
awarded and two are ongoing. Based on information in
the tender notices, these tenders cover only 19 of the
102 Belgian hospitals (general and university hospitals:
53 hospitals in Flanders, 12 in the Brussels-Capital
Region, and 37 in Wallonia). Of these tender notices,
only one was published for Flanders, covering four
hospitals in the province of Flemish Brabant (ongoing).
In the case of rituximab, biosimilar Truxima® first
launched in July 2018, whereas the first notice of intent
to tender was only published in October 2018. In the
meantime, eight tenders have been awarded and two
are ongoing. Based on buying groups, these tenders
cover 38 of the 102 Belgian hospitals. Of these tender
notices, again only one was published for Flanders,
covering four hospitals in Flemish Brabant (ongoing).
Infliximab biosimilars first launched in April 2015. The
first notice of intent to tender was only published in
October 2015. After more than four years, still, some
hospitals have not tendered for infliximab. It is, how-
ever, unclear how many hospitals have not tendered,
as for infliximab some hospitals appear to have joined
existing tender contracts at a later point in time.
A second hurdle for the use of biosimilars in the
hospital setting is the use of criteria other than price in
some tenders that tend to favour the originator product,
e.g. requests for scientific support (grants, conferences).
This finding is in line with results from the KPMG report
‘Improving healthcare delivery in hospitals by optimized
utilization of medicines’ of 2019 [30]. Additionally, hos-
pitals can request free goods via medical need pro-
grammes that can only exist for the originator product.
The opening of tenders and the correct use of tender
criteria was addressed in two circular letters; from the
government in 2016 and from the competent authority
in 2019. Apart from these circular letters, in October 2019,
the Belgian competition authority started an investiga-
tion onpotential anti-competitive behaviour that restricts
the use of biosimilars in the hospital setting [31,32].
Product-specific barriers can as well be identified for
rituximab and pegfilgrastim. A patent litigation case
related to patents for treatment of hematologic malig-
nancies and of joint damage with rituximab and pos-
sible infringement by the entry of biosimilars in
Belgium delayed access of Sandoz’s biosimilar up to
September 2019 [33], while the judgement on the
invalidity of these two patents on a European level
was decided in November 2017 and November 2018
(appeal proceedings are still pending), respectively
[34,35]. In 2017, Mundipharma already lost a patent
litigation case concerning possible infringement of
their rituximab biosimilar. In the case of pegfilgrastim,
the inclusion of biosimilar and originator pegfilgrastim
in the same lot as lipegfilgrastim that has a higher
reimbursement price, makes it almost impossible for
pegfilgrastim products to win a tender, even by pro-
viding high discounts. It is currently studied how this
barrier can be overcome.
2.2. Retail market
In the hospital setting, the use of biosimilars is driven
by cost savings or potentially other criteria in the
tender process and the switch is facilitated by clear
formulary decisions and relatively small efforts to
change IV bags. In the retail setting on the other
hand, there is no such enforcement, as both the push
and pull mechanism lack. After mandatory price cuts,
the price difference between biosimilar and reference
product is limited (Table 3). So why go through the
burden of change for only a marginal additional cost
saving, which does not provide any benefit to the
physician? Moreover, different devices for
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subcutaneous administration complicate switching
and ask for more time investment from physicians
and pharmacists, while there are limited possibilities
related to products dispensed in the retail setting to
request support from companies. In addition, physi-
cians do not appear to be price sensitive. Especially
since price differences between reference and biosimi-
lar product are much lower than between the refer-
ence product and newer treatment options. Also
a personal financial award, as was implemented in
2019 for prescription of biosimilar adalimumab and
etanercept, does not seem to considerably improve
biosimilar uptake. Some physicians find it offending
to be rewarded to prescribe a specific product, while
others would like to see a more substantial
remuneration.
3. Avenues and recommendations to increase
competition in Belgium’s off-patent
biologicals market
Biosimilars offer considerable advantages to health-
care systems. In general, the use of biosimilars leads
to cost savings, price competition, increased patient
access, improved cost effectiveness, incremental inno-
vation, and might contribute to prevention of drug
shortages [10,37]. Although there is probably not an
access issue in Belgium, healthcare budgets under
pressure are of considerable concern.
Based on the discussed barriers impeding
a competitive off-patent biologicals market in
Belgium and learnings from other European countries,
we will propose several suggestions, which may or
may not be compatible with each other, to change
the Belgian off-patent biologicals market towards
a more sustainable, competitive system.
There needs to be clarity on the objectives that wish
to be attained in the Belgian off-patent biologicals
market, and specifically on the role of biosimilars. This
relates to the fact that biosimilars may generate sav-
ings by means of twomechanisms. First, biosimilars are
less expensive due to lower R&D costs. Therefore, in
Belgium, mandatory price decreases of up to 38% are
imposed on the reference product following the entry
of biosimilars to drive down the price of the reference
product. A next step in further exploiting this approach
is that these mandatory price decreases are applied to
originator products once their exclusivity rights expire,
irrespective of whether a biosimilar enters the Belgian
market (as will be the case following revision of the
current cost containment measures, up to −44%). This
approach guarantees savings to the reimbursement
agency, but does not provide an incentive to lower
prices by more than the fixed reduction. Second, bio-
similars may induce long-term price competition with
reference products, generating additional savings.
Based on the general economic relationship between
volume and price of products, it can be hypothesised
that prices of biosimilar and reference products will fall
further when the volume of biosimilars increases. This
approach, thus, requires measures supporting the use
of biosimilars.
Whereas the government has previously implemen-
ted ad hoc measures, Belgium has to evolve towards
a long-term consistent, integrated policy framework
targeting all relevant stakeholders. We propose to
rely on four pillars to build this framework: 1) the
creation of a proactive and transparent climate sup-
porting a level playing field; 2) investment in educa-
tional initiatives; 3) enforcement of the practical
implementation of public procurement law; and 4)
development of physician incentives.
3.1. The creation of a proactive and transparent
climate supporting a level playing field
Policy and decision makers need to foster a proactive
and transparent climate that creates a level playing
field for all off-patent biologicals, including biosimilars,
with a view to inducing long-term competition. This
requires that a number of actions are implemented
prior to and following biosimilar market entry.
3.1.1. Prior to biosimilar market entry
1. In order to stimulate biosimilars to enter the
Belgian market and to encourage reference products
to lower their price, biosimilars and low-cost originator
products could be exempted from the clawback tax
(i.e. a tax calculated on sales in case the pharmaceutical
budget is exceeded).
2. There is a need for horizon scanning to predict
when the patent and other exclusivity rights related to
originator biologicals will expire, and when and how
many biosimilars are likely to be granted regulatory
approval by the European Medicines Agency, and
which are likely to enter the Belgian market. Updates
Table 3. Price differences between biosimilar and reference
product in the retail setting (as of January 2020) [36].
Product
Price difference between biosimilar and
reference (%)
Adalimumab 2 units of
40 mg
8%
Adalimumab 6 units of
40 mg
2%
Etanercept 4 units of
50 mg/ml
20%
Etanercept 12 units of
50 mg/ml
17%
Etanercept 4 units of
25 mg/0.5 ml
19%
Filgrastim 5 units of
0.3 mg/0.5 ml
0-3%
Filgrastim 5 units of
0.48 mg/0.5 ml
0-2%
Insuline glargine 5 × 3 ml
100 E/ml
3%
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on patent expiry dates published by the Generics and
Biosimilars Initiative (GaBI) Journal [38] and informa-
tion on medicines under evaluation at the European
Medicines Agency [39] can serve as a guide.
3. Prior to the expiry of patents and other exclusivity
rights on a specific biological product, views of all
relevant stakeholders regarding the use of that off-
patent biological and its biosimilars should be aligned
through a collaborative, multi-stakeholder approach.
The government and other authorities should increas-
ingly involve scientific medical associations as, via
these associations important key opinion leaders can
be reached. With limited price differences in the retail
setting, the attitude of key opinion leaders can greatly
influence originator/biosimilar market dynamics, as
was the case for etanercept in Sweden [40]. In addition,
hospital pharmacist associations can play an important
role in the hospital setting, and working with the local
hospital management can be a way to target physi-
cians. Also, patient organisations can be more involved
to anticipate potential nocebo effects and changes in
treatment adherence. Furthermore, it should be
explored how the different sickness funds can contri-
bute, e.g. by providing mirror-information on prescrib-
ing behaviour.
4. The Belgian competent authority should assign
a dedicated spokesperson to deal with queries from
stakeholders regarding regulatory aspects of biosimi-
lars. At the moment, the potential role of the compe-
tent authority in education and dissemination of
information is underused. Intensified collaboration
with physician associations and the reimbursement
agency is needed to avoid duplication of work.
5. The new ‘programme manager biological and
biosimilar medicines’ appointed by the reimbursement
agency needs to act as a key opinion leader. He needs
to be proactive and visible by participating in seminars
and act as the contact person for different
stakeholders.
6. The development of a protocol describing
a managed switching programme can help to build
trust in biosimilars and assists physicians in their
efforts. In the Netherlands, the hospital pharmacists
together with the medical specialists have built
a Biosmilar Toolbox, which contains a collection of
best practices for biosmilar implementation. In
Scotland, the National Health Service (NHS) shared
case studies for infliximab and etanercept on the
switch from originator to biosimilar on their website
to encourage the different regions to learn from this
experience [41]. National managed switch letters exist
in Scotland that can be adapted to local needs.
7. Competition seems to be more present in the
hospital setting than in the retail setting. A change in
treatment setting for some products from retail to hos-
pital could increase competition and cost savings. In
the Netherlands, TNF-alpha inhibitors such as
etanercept and adalimumab are for this reason
included in the hospital budget since 2012 [42]. On
the other hand, in Sweden a managed entry agreement
with rebates for subcutaneously administered TNF-
alpha inhibitors is used to stimulate competitive pricing
in the retail setting [40]. Following the agreement,
recommendations are made available that inform phy-
sicians which product is the most cost-effective to
prescribe.
3.1.2. Following biosimilar market entry
8. Scientific medical associations need to update
(clinical) guidelines when biosimilars enter the
Belgian market and take into account the price evo-
lution of biological therapies. Based on such an
exercise, they could rank products and offer gui-
dance to physicians on what is the most cost-
effective option to prescribe, be it a low-cost refer-
ence product or a biosimilar. This approach could be
tested in disease areas such as rheumatology, where
for most patients it does not matter with which
biological they start and where a change in product
is acceptable. In addition, the proposed ranking
should create cost-consciousness on the increase in
cost per patient per year of new products, such as
for example JAK inhibitors, versus the added thera-
peutic value these treatments supposedly have.
9. The reimbursement agency needs to revise the
reimbursement conditions of all products in
a therapeutic class following market entry of a specific
biosimilar product with a view to account for the evolu-
tion in cost-effectiveness of these products as a result of
price changes of the biosimilar and reference biological.
This is particularly relevant for product classes with
next-generation products such as G-CSF, where the
market entry of filgrastim biosimilars and associated
price decreases affect the cost-effectiveness of pegfil-
grastim (and its biosimilars) and lipegfilgrastim.
10. The reimbursement agency could regularly pub-
lish aggregated data on biosimilar uptake per product in
the hospital and retail setting on a website and make
a critical appraisal of the situation to create more trans-
parency. In addition, report publicly on the savings gen-
erated frommandatory price reductions and the entry of
biosimilars, where these savings go, and how these
benefit the healthcare budget and care for patients.
3.2. Investment in educational activities
Although the knowledge about and trust in biosimilars
might not be considered a key barrier anymore, further
efforts to increase awareness and acceptance might be
needed and can be relatively easy implemented.
Educational initiatives regarding biological medicines,
including biosimilars, should target both future and
active healthcare professionals. However, although
education is necessary before implementing other
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measures, educational initiatives alone will likely be
insufficient to drive changes in prescribing behaviour.
1. Education needs to start early and should include
future healthcare professionals. Therefore, it is pro-
posed to include more information on biological med-
icines, including biosimilars, in the curriculum of (bio-)
medical and pharmacy students. Also, an increased
focus on societal responsibility and rational prescribing
of medicines might pay off on the long term. However,
due to only small price differences, this will have lim-
ited impact on biosimilar uptake on the short term.
This initiative can be implemented by urging universi-
ties to include courses in the training of medical stu-
dents on how marketing authorization of medicines
works, health economic aspects of first line and second
line therapy and the difference in cost when changing
to second line. The reimbursement agency needs to
support these courses and be involved in teaching.
2. Efforts to inform and communicate with physi-
cians and pharmacists should use proven effective
channels like guidelines, information letters from hos-
pital management, and communication from medical
associations. Education of physicians could be linked
to accreditation. Previous research has suggested that
there is no lack of available information and has
stressed the importance of an active communication
strategy tailored to reach the target audience [43].
3. It is best to have educational activities initiated by
an independent organisation like the government,
competent authority or scientific medical associations.
Support from the government to an independent
expert group that can set up educational initiatives
and talk to hospitals and patient organizations could
be a solution. In the Netherlands, the ‘Initiatiefgroep
Biosimilars Nederland’ (IBN) offers via the ‘Biosimilars
op maat’ project e-learning modules and on-site train-
ing for hospitals by a group of experts [44,45]. Their
expertise and material could be leveraged and
adapted for the Belgian market.
4. The KCE report of 2013 reports that medical scien-
tific literature and medical conferences are the main
sources of information regarding biosimilars for physi-
cians [10]. However, pharmaceutical companies can play
an important role as they have good access to physicians
via sales representatives and the organisation of sympo-
sia. It is important that information given on symposia is
neutral and not linked to the marketing of a specific
product. However, increased marketing efforts by com-
panies for biosimilars, like for any other new product,
require investments and this might be reflected in
a lower level of discounts that can be offered.
3.3. Enforcement of the practical implementation
of public procurement law
When correctly applied, tenders create competition
between biosimilar and reference product in the
hospital setting. The implementation of tender proce-
dures in Belgium can be improved by several
initiatives.
1. In order to prioritize tenders for pharmaceuticals,
it is important to implement horizon scanning.
A special unit should be established to support hospi-
tals with information on upcoming loss of exclusivities
of top-selling molecules and the entry of biosimilars in
Belgium. In Denmark and the United Kingdom (UK),
discussions often start years before patent expiry and
possible entry of biosimilars in order to align stake-
holders. New contracts should also take into account
future entry of products and the length of the contract
should be set accordingly.
2. The tender process could be simplified to reduce
workload for hospitals and industry. A template can be
made available with criteria to be considered, while
criteria other than price can be taken into account to
allow for product differentiation and incremental inno-
vation. Guidance to hospitals can be provided on how
to set up a tender unit and educate personnel.
3. Adherence to laws on public procurement is key
to ensure an equal level playing field and induce com-
petition. A close follow-up and appropriate enforce-
ment measures are needed to guarantee the timely
opening of tenders after the entry of biosimilars and
the adoption of appropriate criteria in the tender pro-
cess. In this respect, the Belgian Competition Authority
needs to conduct audits of hospital tenders for biolo-
gicals, including biosimilars, and needs to follow up
hospitals' adherence with laws on public procurement.
4. In order to reduce workload for hospitals and
industry, tenders could be organised on a larger
scale, for example via hospital networks or on
a national level. Organising the tender process on
a national level would have the advantage that one
single expert unit can ensure a smooth process sup-
ported by adequate preparation. In addition, savings
can go directly to the healthcare system. When tender-
ing on a national level, multiple winners should be
selected to ensure plurality of supply and the length
of the contract could be limited to a maximum of two
years to stimulate market dynamics. To divide the
market among players, different ideas can be pro-
posed. The NHS England experimented with
a ‘managed market share tender approach’ for the
public procurement of adalimumab in 2018 [46].
Depending on the competitiveness of the bid, the
company has access to a greater or smaller part of
the market, which is divided in 11 regions. A second
option is to work with a ranking like in Norway and to
recommend products based on the first year treatment
cost for each indication [47]. In order to make tender-
ing on a national level feasible for hospitals, the hospi-
tal financing system needs to be reformed to address
the resulting shortfall in income from procurement
savings for hospitals. In addition, savings accruing to
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the reimbursement agency can be partially used to
remunerate physicians and nurses for their time invest-
ment in switching patients through gainsharing
arrangements.
3.4. Development of physician incentives
As a key stakeholder affecting the long-term sustain-
ability of the biologicals market, physicians should be
motivated and appropriately incentivized to prescribe
rationally. It is specifically important that incentives are
precisely formulated and that the benefit to physicians
is clear. This does not mean that the benefit should go
to individual physicians, but rather to support the
hospital or hospital department. In addition, physician
incentives should allow freedom of prescribing.
Several actions can be proposed to increase physician
engagement towards the use of biosimilars.
1. Position statements from medical associations
or scientific associations on biosimilars and switching
can help to build trust among physicians and give
them confidence to prescribe biosimilars. Physicians
are more likely to accept information and guidance
from key opinion leaders and peers than from autho-
rities. These position statements also need to be
updated over time in concordance with evolving
scientific insights into biologicals, including biosimi-
lars. The Belgian inflammatory bowel disease
research and development group (BIRD) and the
Belgian Royal Society of Rheumatology published
a cautious position statement in 2015 [48,49]. The
BIRD group published new, more proactive state-
ments for 2017 and 2019 [50,51]. It is unclear if and
how the existing position statements have influ-
enced prescribing behaviour in a positive or negative
way.
2. The implementation of guidelines could provide
advice to physicians to prescribe the most cost-
effective product, without enforcement. This is
a practice that tends to work well in other countries
and is established in e.g. Sweden, Norway, Denmark,
and the UK. In Germany and Austria, health insurance
funds (‘sickness funds’) provide as well information to
physicians to guide the rational prescribing of medi-
cines. However, it will take time for physicians to adapt
to this new system. One step further would be to
develop an indicator for how well physicians follow
prescribing guidelines or for when physicians prescribe
the most cost-effective product.
3. Although quota for prescribing low-cost medi-
cines have already been implemented in Belgium,
there is scope to further fine-tune this measure by,
for instance, moving away from a target for low-cost
medicines to a target for the lowest-cost medicine in
the retail setting; or by calculating a separate target for
lowest-cost biological medicines (excluding chemical
medicines). The implementation of a target agreement
should be accompanied by follow-up on adherence
and a reward or punishment system. In Germany, tar-
get agreements are used for many medical products,
including biosimilars. These prescription targets are set
for each region in Germany and can differ per molecule
and per specialisation.
4. Gainsharing, where part of the savings or benefits
from using biosimilars flow back to the hospital depart-
ment and are transparent for prescribing physicians,
can be a strong incentive for the use of biosimilars. This
can especially work well for products used in the retail
setting, where, in contrast to the hospital setting, the
use is not driven by formulary decisions. Potential sav-
ings should be used to create tangible benefits rather
than just providing a financial reward. The government
could invest in study nurses to help support physicians
as they will need to allocate more time to patients that
will switch from the reference product to the biosimi-
lar. In Scotland, the ‘invest to save’ approach was
recognised and additional staffing resources were
arranged to manage the switch from originator to
biosimilar etanercept. In Denmark, more nurses were
present during the first weeks of the tender agreement
for biosimilar adalimumab to help switch patients. This
resulted in more than 90% of patients being switched
to biosimilar adalimumab in three weeks’ time [52].
The Belgian government could also invest in applica-
tions to improve patient flow and educational material,
like the national managed switch letters in
Scotland [41].
5. When a benefit is more visible, it might encou-
rage physicians to change prescribing behaviour. For
this, the communication via newsletters that outline
what was realised with the savings from a certain per-
centage of biosimilar prescription can motivate physi-
cians. Especially when part of these savings have been
used to make investments in their therapeutic area.
6. When cost-effective, a broader reimbursement
(indications, posology, medical tests) or change in
treatment line following price decreases for an active
substance can offer more options for physicians to
prescribe biologicals and improve patient care. These
are two factors that physicians find important.
7. The use of an electronic prescribing system offers
opportunities to support rational prescribing.
Prescribing software should be linked to price lists and
show for each product price information to increase
price awareness among physicians. The most cost-
effective product can be presented first in the ranking.
4. Conclusions
The current biosimilar landscape in Belgium is charac-
terised by low biosimilar uptake and the implementation
of several ad hoc policy measures. Instead, the govern-
ment should foster a competitive climate and establish
a level playing field for both biosimilar and reference
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product. Even though high biosimilar market shares are
not a goal in itself, but rather the generation of cost
savings by leveraging competition from biosimilars, we
question whether Belgium has maximized the savings
potential at the moment, even with a multitude of cost
containment measures. To fully realise the potential of
biosimilar competition, we advocate that all stakeholders
develop a long-term coherent, integrated policy frame-
work that is built on the following four pillars: i) the
creation of a proactive and transparent climate support-
ing a level playing field for both biosimilar and reference
product, includingpublic dissemination of how savings at
the level of the Belgian healthcare system are used, ii)
investment in educational activities, including raising
awareness of societal responsibilities, iii) enforcement of
the practical implementation of public procurement law,
and iv) development of physician incentives. Furtherwork
is needed to translate each of these four pillars into
specific policy measures to be implemented, in particular
with respect to physician incentives and prescribing
behaviour.
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